Waverly Advisors LLC Boosts Stake in Humacyte, Inc. (NASDAQ:HUMA)

Waverly Advisors LLC raised its stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 331.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 274,579 shares of the company's stock after acquiring an additional 211,009 shares during the quarter. Waverly Advisors LLC owned approximately 0.22% of Humacyte worth $1,387,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in HUMA. Vontobel Holding Ltd. bought a new position in shares of Humacyte in the fourth quarter worth about $50,000. Petros Family Wealth LLC bought a new position in Humacyte in the 4th quarter valued at approximately $50,000. Syon Capital LLC bought a new position in Humacyte in the 4th quarter valued at approximately $54,000. Ameriprise Financial Inc. bought a new position in Humacyte in the 4th quarter valued at approximately $58,000. Finally, Hsbc Holdings PLC bought a new position in Humacyte in the 4th quarter valued at approximately $62,000. Institutional investors own 44.71% of the company's stock.

Humacyte Stock Performance

NASDAQ:HUMA traded up $0.09 during trading hours on Wednesday, reaching $2.57. The stock had a trading volume of 2,065,979 shares, compared to its average volume of 3,772,106. Humacyte, Inc. has a 52 week low of $1.15 and a 52 week high of $9.97. The company has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $3.34. The stock has a market capitalization of $398.04 million, a PE ratio of -1.92 and a beta of 1.64.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to analysts' expectations of $0.46 million. Equities research analysts predict that Humacyte, Inc. will post -1.27 EPS for the current year.

Insider Activity

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the firm's stock in a transaction on Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the acquisition, the director now directly owns 91,207 shares of the company's stock, valued at approximately $120,393.24. This represents a 121.34% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Dale A. Sander purchased 20,000 shares of the firm's stock in a transaction on Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. The trade was a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock worth $118,224 over the last quarter. 5.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on HUMA. Benchmark lowered their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research note on Tuesday, May 13th. HC Wainwright assumed coverage on Humacyte in a research note on Wednesday, May 14th. They set a "buy" rating and a $4.00 price objective for the company. Finally, Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.